相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。A Randomized Phase II Study Adding Axitinib to Pemetrexed-Cisplatin in Patients with Malignant Pleural Mesothelioma: A Single-Center Trial Combining Clinical and Translational Outcomes
Wieneke A. Buikhuisen et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial
Gerard Zalcman et al.
LANCET (2016)
Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations
Raphael Bueno et al.
NATURE GENETICS (2016)
Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions
Naveen S. Vasudev et al.
ANGIOGENESIS (2014)
Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial
Martin Reck et al.
LANCET ONCOLOGY (2014)
Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma
G. L. Ceresoli et al.
BRITISH JOURNAL OF CANCER (2013)
Phase 2 Study of Sorafenib in Malignant Mesothelioma Previously Treated with Platinum-Containing Chemotherapy
Sophie Papa et al.
JOURNAL OF THORACIC ONCOLOGY (2013)
Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label, multicentre, randomised phase 3 study
Wieneke A. Buikhuisen et al.
LANCET ONCOLOGY (2013)
A phase II clinical trial of the Vascular Disrupting Agent BNC105P as second line chemotherapy for advanced Malignant Pleural Mesothelioma
Anna K. Nowak et al.
LUNG CANCER (2013)
Multicenter, Double-Blind, Placebo-Controlled, Randomized Phase II Trial of Gemcitabine/Cisplatin Plus Bevacizumab or Placebo in Patients With Malignant Mesothelioma
Hedy L. Kindler et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Phase II Study of Dasatinib in Patients with Previously Treated Malignant Mesothelioma (Cancer and Leukemia Group B 30601) A Brief Report
Arkadiusz Z. Dudek et al.
JOURNAL OF THORACIC ONCOLOGY (2012)
A Phase II Study of Intermittent Sunitinib Malate as Second-Line Therapy in Progressive Malignant Pleural Mesothelioma
Anna K. Nowak et al.
JOURNAL OF THORACIC ONCOLOGY (2012)
A multicenter phase II study of cisplatin, pemetrexed, and bevacizumab in patients with advanced malignant mesothelioma
Jonathan E. Dowell et al.
LUNG CANCER (2012)
The predictive role of serum VEGF in an advanced malignant mesothelioma patient cohort treated with thalidomide alone or combined with cisplatin/gemcitabine
Steven Chuan-Hao Kao et al.
LUNG CANCER (2012)
Vatalanib in malignant mesothelioma: A phase II trial by the Cancer and Leukemia Group B (CALGB 30107)
Thierry Jahan et al.
LUNG CANCER (2012)
The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by Tumor-Vascular Disrupting Agents
Dietmar W. Siemann
CANCER TREATMENT REVIEWS (2011)
Prognostic but not predictive role of platelet-derived growth factor receptors in patients with recurrent glioblastoma
Janna Paulsson et al.
INTERNATIONAL JOURNAL OF CANCER (2011)
Phase II Study of Cediranib in Patients with Malignant Pleural Mesothelioma SWOG S0509
Linda L. Garland et al.
JOURNAL OF THORACIC ONCOLOGY (2011)
Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study
Tom Treasure et al.
LANCET ONCOLOGY (2011)
Phase II Study of Asparagine-Glycine-Arginine-Human Tumor Necrosis Factor α, a Selective Vascular Targeting Agent, in Previously Treated Patients With Malignant Pleural Mesothelioma
Vanesa Gregorc et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
A Phase II Study of Sorafenib in Malignant Mesothelioma Results of Cancer and Leukemia Group B 30307
Sarita Dubey et al.
JOURNAL OF THORACIC ONCOLOGY (2010)
Clinical Significance of Serum Vascular Endothelial Growth Factor in Malignant Pleural Mesothelioma
Akihiro Yasumitsu et al.
JOURNAL OF THORACIC ONCOLOGY (2010)
Regulation of Angiogenesis by Macrophages, Dendritic Cells, and Circulating Myelomonocytic Cells
Zhao Ming (David) Dong et al.
CURRENT PHARMACEUTICAL DESIGN (2009)
Cellular and molecular pathways linking inflammation and cancer
Chiara Porta et al.
IMMUNOBIOLOGY (2009)
Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system
Hellmut G. Augustin et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2009)
Tumour vascular disrupting agents: combating treatment resistance
G. M. Tozer et al.
BRITISH JOURNAL OF RADIOLOGY (2008)
Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: Implications for antiangiogenic drugs as chemosensitizing agents
Yuval Shaked et al.
CANCER CELL (2008)
Profiling tumor-associated markers for early detection of malignant mesothelioma: An epidemiologic study
Monica Amati et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2008)
Imatinib mesylate enhances therapeutic effects of gemcitabine in human malignant mesothelioma xenografts
Pietro Bertino et al.
CLINICAL CANCER RESEARCH (2008)
Pathways Mediating Resistance to Vascular Endothelial Growth Factor - Targeted Therapy
Lee M. Ellis et al.
CLINICAL CANCER RESEARCH (2008)
Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033
Charles D. Blanke et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Modes of resistance to anti-angiogenic therapy
Gabriele Bergers et al.
NATURE REVIEWS CANCER (2008)
The therapeutic efficacy of anti-vascular endothelial growth factor antibody, bevacizumab, and pemetrexed against orthotopically implanted human pleural mesothelioma cells in severe combined immunodeficient mice
Qi Li et al.
CLINICAL CANCER RESEARCH (2007)
Alternative vascularization mechanisms in cancer - Pathology and therapeutic implications
Balazs Dome et al.
AMERICAN JOURNAL OF PATHOLOGY (2007)
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer
Alan Sandler et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
cNGR: A novel homing sequence for CD13/APN targeted molecular imaging of murine cardiac angiogenesis in vivo
Alexandra Buehler et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2006)
Tumor-driven paracrine platelet-derived growth factor receptor α signaling is a key determinant of stromal cell recruitment in a model of human lung carcinoma
ML Tejada et al.
CLINICAL CANCER RESEARCH (2006)
Toll-like receptors, inflammation and cancer
MF Tsan
SEMINARS IN CANCER BIOLOGY (2006)
Expression and prognostic significance of hypoxia-inducible factor 1 alpha (HIF-1 alpha) in malignant pleural mesothelioma (MPM)
A Klabatsa et al.
LUNG CANCER (2006)
Signal transduction of inflammatory cytokines and tumor development
Akihiko Yoshimura
CANCER SCIENCE (2006)
Antiangiogenic therapies for mesothelioma
JE Dowell et al.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2005)
Prognostic significance of vascular endothelial growth factor, tumor necrosis, and mitotic activity index in malignant pleural mesothelioma
F Demirag et al.
CHEST (2005)
Limited efficacy of imatinib mesylate in malignant mesothelioma: A phase II trial
A Mathy et al.
LUNG CANCER (2005)
A potential oncogenic activity of platelet-derived growth factor D in prostate cancer progression
CV Ustach et al.
CANCER RESEARCH (2004)
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
H Hurwitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis
SM Wilhelm et al.
CANCER RESEARCH (2004)
Tumor necrosis correlates with angiogenesis and is a predictor of poor prognosis in malignant mesothelioma
JG Edwards et al.
CHEST (2003)
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma
NJ Vogelzang et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Tumorigenesis and the angiogenic switch
G Bergers et al.
NATURE REVIEWS CANCER (2003)
Dominant negative PDGF-C inhibits growth of Ewing family tumor cell lines
JP Zwerner et al.
ONCOGENE (2002)
Thalidomide in multiple myeloma
P Richardson et al.
BIOMEDICINE & PHARMACOTHERAPY (2002)
Angiogenesis is an independent prognostic factor in malignant mesothelioma
JG Edwards et al.
BRITISH JOURNAL OF CANCER (2001)
Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.
BJ Druker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma
L Strizzi et al.
JOURNAL OF PATHOLOGY (2001)
Mosaic blood vessels in tumors: Frequency of cancer cells in contact with flowing blood
YS Chang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
Enhancement of tumor necrosis factor a antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13)
F Curnis et al.
NATURE BIOTECHNOLOGY (2000)
The expression and distribution of the hypoxia-inducible factors HIF-1α and HIF-2α in normal human tissues, cancers, and tumor-associated macrophages
KL Talks et al.
AMERICAN JOURNAL OF PATHOLOGY (2000)
分享论文
